https://pubmed.ncbi.nlm.nih.gov/36216931/?dopt=Abstract
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
of a
https://colorectalcancer.org/article/mirati-begin-clinical-trials-treatment-krasg12d-colorectal-cancer
Mirati to begin clinical trials of treatment for KRASG12D colorectal cancer | Colorectal Cancer...
MRTX1133 is a potential first-in-class oral treatment for patients with the KRASG12D colorectal cancer mutation.
clinical trialstreatment formiratibegin